SoFi CEO enters prepaid forward contract on 1.5 million shares
ADMA Biologics, Inc. (NASDAQ:ADMA) President and CEO Adam S. Grossman recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On March 19, 2025, Grossman sold a total of 21,000 shares of common stock in two separate transactions. The shares were sold at a price of $18.92 each, amounting to a total value of $397,320. The transaction comes as ADMA’s stock has delivered an impressive 215% return over the past year, with the company now commanding a market capitalization of $4.7 billion.
In addition to the sales, Grossman acquired 15,000 shares of common stock through an option exercise at a price of $5.40 per share, totaling $81,000. Following these transactions, Grossman holds 2,061,850 shares directly and maintains indirect ownership of additional shares through entities Areth, LLC and Hariden, LLC. According to InvestingPro, analysts maintain a Strong Buy consensus on ADMA, with price targets ranging from $19.09 to $32.00 per share. The company’s financial health score is rated as "Excellent," with 12 additional ProTips available to subscribers.
These transactions were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan for buying or selling stock to avoid accusations of insider trading.
In other recent news, ADMA Biologics reported impressive financial results for the fourth quarter of 2024, with earnings per share (EPS) significantly surpassing expectations at $0.46, compared to the forecast of $0.15. The company’s revenue also exceeded predictions, reaching $117.5 million, marking a 59% year-over-year growth. For the full year, ADMA’s total revenue was $426.5 million, a 65% increase from the previous year, with a gross profit margin improving to 51.5% from 34.4% in 2023. Looking ahead, ADMA Biologics has set a robust revenue guidance for 2025, targeting over $490 million.
Analyst firms have also weighed in on ADMA Biologics’ prospects. Mizuho (NYSE:MFG) Securities increased its price target for ADMA to $32, maintaining an Outperform rating, citing significant revenue potential for its ASCENIV product. Cantor Fitzgerald maintained its $25 price target and Overweight rating, noting the company’s pattern of conservative revenue guidance followed by upward revisions. Analysts at Cantor also highlighted the potential benefits of ADMA’s enhanced yield production process, which could increase the production of finished intravenous immunoglobulin by approximately 20%.
These developments underscore ADMA Biologics’ ongoing growth and success in the biopharmaceutical market. The company’s strategic focus on expanding plasma collection and production capabilities, along with its penetration into the primary immunodeficiency market, continues to drive its financial performance. With recent analyst endorsements and strong earnings results, ADMA Biologics remains a company of interest for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.